Evidence map›Paper›PMID 37516774›Full record

ArticleNature communications2023

Cryo-EM structure of a RAS/RAF recruitment complex.

Eunyoung Park, Shaun Rawson, Anna Schmoker, Byeong-Won Kim, Sehee Oh, Kangkang Song, Hyesung Jeon, Michael J Eck

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Eunyoung Park *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Shaun Rawson *Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-2973-2630
Anna SchmokerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0003-2830-5650
Byeong-Won KimDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-7722-0090
Sehee OhDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Kangkang SongDepartment of Biochemistry & Molecular Biotechnology, University of Massachusetts Chan Medical School, 364 Plantation St, Worcester, MA, 01605, USA.
Hyesung JeonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. hjeon@crystal.harvard.edu.ORCID http://orcid.org/0000-0002-0034-5469
Michael J EckDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. eck@crystal.harvard.edu.ORCID http://orcid.org/0000-0003-4247-9403
Harvard University · USDana-Farber Cancer Institute · USUniversity of Massachusetts Chan Medical School · US

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tracy T Batchelor · 2013 to 2026
$33.5M
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2012 to 2021
$17.8M
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathwayR35CA242461 · NCI · DANA-FARBER CANCER INST · PI ECK, MICHAEL J · 2019 to 2025
$7.4M
Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinasesR50CA221830 · NCI · DANA-FARBER CANCER INST · PI PARK, EUNYOUNG · 2017 to 2021
$942k
NCI NIH HHS P01 CA154303NCI NIH HHS P50 CA165962NCI NIH HHS P50CA165962NCI NIH HHS PO1CA154303NCI NIH HHS R35 CA242461NCI NIH HHS R50 CA221830
6 · The paper itself

Abstract

RAF-family kinases are activated by recruitment to the plasma membrane by GTP-bound RAS, whereupon they initiate signaling through the MAP kinase cascade. Prior structural studies of KRAS with RAF have focused on the isolated RAS-binding and cysteine-rich domains of RAF (RBD and CRD, respectively), which interact directly with RAS. Here we describe cryo-EM structures of a KRAS bound to intact BRAF in an autoinhibited state with MEK1 and a 14-3-3 dimer. Analysis of this KRAS/BRAF/MEK1/14-3-3 complex reveals KRAS bound to the RAS-binding domain of BRAF, captured in two orientations. Core autoinhibitory interactions in the complex are unperturbed by binding of KRAS and in vitro activation studies confirm that KRAS binding is insufficient to activate BRAF, absent membrane recruitment. These structures illustrate the separability of binding and activation of BRAF by RAS and suggest stabilization of this pre-activation intermediate as an alternative therapeutic strategy to blocking binding of KRAS.

Indexed as

Proto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Cell MembraneCryoelectron MicroscopyMAP Kinase Signaling SystemProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID37516774
PMCPMC10387098
OpenAlexW4385374867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.